Our Early-Stage Compounds​

Exelixis has a diverse portfolio of small molecule and biologics programs moving forward, covering a broad range of targets and therapeutic modalities. We are committed to further enhancing our early-stage pipeline and expanding our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians.

Program Name
Mechanism
Phase
  • Discovery/
    Preclinical
  • IND
  • Phase 1a
  • Phase 1b
  • Phase 2/3
XL092
Next-generation TKI targeting MET/
VEGFR/AXL/MER
Next-generation TKI targeting MET/
VEGFR/AXL/MER
  • Phase 1b
XB002
Next-generation TF-targeting ADC
Next-generation TF-targeting ADC
  • Phase 1a
XL102
Potent, selective, orally bioavailable CDK7 inhibitor
Potent, selective, orally bioavailable CDK7 inhibitor
  • Phase 1a
XL114
CBM pathway inhibitor
CBM pathway inhibitor
  • Phase 1a
XB010
Next-generation 5T4-targeting ADC
Next-generation 5T4-targeting ADC
  • Discovery/
    Preclinical
Aurigene Collaboration Programs
CDK12 and MALT1 inhibitors
CDK12 and MALT1 inhibitors
  • Discovery/
    Preclinical
Invenra Collaboration Programs
PD-L1 + CD47 and PD-L1 + NKG2A
PD-L1 + CD47 and PD-L1 + NKG2A
  • Discovery/
    Preclinical
StemSynergy Collaboration Programs
CK1α activators and selective Notch inhibitors
CK1α activators and selective Notch inhibitors
  • Discovery/
    Preclinical
STORM Therapeutics Collaboration Programs
ADAR1
ADAR1
  • Discovery/
    Preclinical
Exelixis Discovery Programs
G9a inhibitors
G9a inhibitors
  • Discovery/
    Preclinical
Biologics Programs Invenra, NBE Therapeutics, Catalent, GamaMabs WuXi & Adagene Collaborations
AMHR2, ROR1/2, TF, DLL3
AMHR2, ROR1/2, TF, DLL3
  • Discovery/
    Preclinical
  • TKI = tyrosine kinase inhibitor
  • CDK7 = cyclin-dependent kinase 7
  • CK1α = casein kinase 1 alpha
  • TF = tissue factor
  • ADC = antibody-drug conjugate
  • IND = Investigational New Drug application
  • CDK12 = cyclin-dependent kinase 12
  • NKG2A = natural killer cell receptor group 2A
  • ADAR1 = adenosine deaminase 1
  • CBM = CARD11-BCL10-MALT1

Cabozantinib Pipeline

Explore the diverse development program for our flagship molecule